MAOI stands for monoamine oxidase inhibitor, a class of medication that blocks an enzyme in your body called monoamine oxidase. This enzyme normally breaks down three key brain chemicals that regulate mood: serotonin, norepinephrine, and dopamine. By blocking the enzyme, MAOIs allow those chemicals to build up to higher levels in the brain, which can relieve depression and help with certain other conditions.
First introduced in the 1950s, MAOIs were among the earliest antidepressants ever developed. They remain effective, sometimes remarkably so, but dietary restrictions and drug interactions have pushed them into a backup role behind newer antidepressants. Today they’re considered third-line medications for treatment-resistant depression and are widely regarded as underutilized.
How MAOIs Work in the Brain
Your brain cells communicate through chemical messengers called neurotransmitters. After these messengers do their job, the enzyme monoamine oxidase breaks them down so they don’t accumulate. In some people, this cleanup process is too aggressive, leaving levels of serotonin, norepinephrine, and dopamine lower than they should be. Low levels of these chemicals are linked to depression, anxiety, and other mood disorders.
MAOIs block the monoamine oxidase enzyme from doing its work. With the enzyme out of commission, more serotonin, norepinephrine, and dopamine stay available in the spaces between brain cells, improving mood signaling. This triple-neurotransmitter effect is part of what makes MAOIs powerful. Most modern antidepressants target only one or two of these chemicals.
Two Types of the Enzyme: MAO-A and MAO-B
Monoamine oxidase actually comes in two forms. MAO-A has a stronger preference for serotonin and norepinephrine, the chemicals most closely tied to mood. MAO-B prefers a different set of compounds, though both forms break down dopamine and tyramine at roughly equal rates.
This distinction matters because different medications target different forms. Blocking MAO-A raises serotonin and norepinephrine, producing an antidepressant effect. Blocking MAO-B raises dopamine levels in movement-related brain areas, which helps with Parkinson’s disease. Older MAOIs like phenelzine and tranylcypromine block both forms at once. Newer, more targeted drugs block just one.
What MAOIs Are Used to Treat
Depression is the most established use, particularly depression that hasn’t responded to other treatments. MAOIs can also be effective for panic disorder, social phobia, and depression with atypical features (symptoms like oversleeping, overeating, and heavy feelings in the arms and legs rather than the classic insomnia and appetite loss).
On the neurological side, MAO-B selective inhibitors like selegiline and rasagiline are FDA-approved for Parkinson’s disease. Selegiline is used alongside standard Parkinson’s medication when the primary treatment starts losing effectiveness. Safinamide serves a similar role, helping patients who experience “off” episodes where their Parkinson’s symptoms break through. The American Academy of Neurology recognizes MAO-B inhibitors as an option for early Parkinson’s disease with mild motor symptoms.
Irreversible vs. Reversible MAOIs
Traditional MAOIs bind permanently to the monoamine oxidase enzyme, destroying it. Your body has to manufacture entirely new enzyme molecules before normal function returns, which can take about two weeks. This is why these drugs are called irreversible inhibitors, and it’s the root cause of most of their safety concerns. Phenelzine and tranylcypromine fall into this category.
A newer subclass called RIMAs (reversible inhibitors of MAO-A) works differently. These drugs latch onto the enzyme temporarily and can be pushed off when competing molecules show up. This is a critical safety advantage: if you eat a food high in tyramine, the tyramine can displace the drug from the enzyme in your gut and liver, allowing your body to process the tyramine normally. Moclobemide is the most widely available RIMA, though it isn’t sold in the United States. Research into newer RIMAs continues, with some showing full brain enzyme inhibition that reverses within 24 hours of a single dose.
The Tyramine Problem: Why Diet Matters
The most distinctive thing about taking an MAOI is the dietary restrictions. Tyramine is a naturally occurring compound found in many aged, fermented, and cured foods. Normally, monoamine oxidase in your gut and liver breaks down tyramine before it reaches your bloodstream. When that enzyme is blocked by an MAOI, tyramine passes through into circulation, where it triggers a flood of norepinephrine release. The result is a sharp spike in blood pressure that typically lasts one to three hours. This reaction, historically called the “cheese effect,” can be dangerous.
Foods that are highest in tyramine include:
- Aged cheeses: especially artisanal or matured varieties (cheddar, smear-ripened cheeses)
- Cured and fermented meats: prosciutto, salami, dry-cured ham, coppa, and chicken livers
- Fermented soy products: soy sauce (some samples contain extremely high tyramine levels), miso soup
- Fermented vegetables: sauerkraut and kimchi, with some sauerkraut samples containing 400 to 900 mg/kg of tyramine
- Yeast extracts: Marmite, Vegemite, Bovril, and similar spreads (322 to 650 mg/kg)
- Certain fish: amberjack, anchovy, mackerel, and tuna, particularly when not fresh
- Some alcoholic beverages: especially home-brewed or artisanal beers and wines
Fresh, unprocessed versions of most foods are generally fine. The tyramine content rises with age, fermentation, and bacterial activity. A fresh piece of chicken is safe; chicken liver is not. Fresh mozzarella is low risk; aged cheddar is high risk. The pattern is consistent: the more something has been aged or fermented, the more cautious you need to be.
Drug Interactions and Serotonin Syndrome
Beyond food, MAOIs interact with a wide range of other medications. The most serious risk is serotonin syndrome, a potentially life-threatening condition that occurs when serotonin levels climb too high. This can happen when an MAOI is combined with other drugs that also raise serotonin, including common antidepressants like SSRIs and SNRIs, certain pain medications, and some cough suppressants.
Serotonin syndrome symptoms range from mild (shivering, diarrhea, restlessness) to severe (high fever, seizures, muscle rigidity). Because of this risk, switching between an MAOI and another antidepressant requires a washout period, often two weeks or longer, to let the first drug fully clear your system. This is one of the practical realities that makes prescribing MAOIs more complicated than other antidepressants.
Why MAOIs Are Still Prescribed
Despite the dietary rules and interaction risks, MAOIs occupy an important place in treatment. For people who haven’t responded to multiple other antidepressants, MAOIs can be genuinely transformative. Their ability to raise all three major mood-related neurotransmitters at once gives them a pharmacological breadth that most newer drugs lack.
The practical barriers are real but manageable. People who take MAOIs learn which foods to avoid, carry lists of drug interactions, and stay in close communication with their prescriber. For someone who has tried several antidepressants without relief, these trade-offs are often worth it. The bigger issue may be that many clinicians today have limited experience prescribing them, which contributes to their underuse in patients who might genuinely benefit.